" class="no-js "lang="en-US"> David Hipkiss - Medtech Alert
Tuesday, October 21, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
David Hipkiss

David Hipkiss

About David Hipkiss

Experienced Chief Executive Officer with a successful track record in the pharmaceuticals industry with both Private and Public companies. Strong corporate business development professional skilled in Pharmaceutics, Medical Devices, Biotechnology, Licensing, Fundraising and Exits.

Related Story

Appointments

 Enesi Pharma Appoints Elizabeth Eagling-Vose

Enesi Pharma Appoints Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations

September 7 2021

Enesi Pharma Ltd (“Enesi”), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases […]